品系优势：

• 成熟的T、B、NK细胞缺失，巨噬细胞吞噬功能受限，髓系细胞发育阻碍，是市⾯上免疫缺陷最彻底的⼩⿏模型之⼀，可⽤于⼈源化⼩⿏模型的构建；
• 具有较⾼的辐照耐受性，适合核药及放射性疗法的药效学评估；
• NOD背景来源的Sirpα基因（Sirpα^NOD）替代了BALB/c背景的Sirpα基因，对各种来源的CDX和PDX⾼度兼容；
• 补体系统功能完整，是研究补体依赖细胞毒性（CDC）的重要⼯具。

应用场景：

• CDX和PDX建模； 
• ADC疗法评估；
• ⼩分⼦药效评估； 
• 核药及放射性疗法评估； 
• 细胞治疗有效性评估； 
• 构建⼈免疫系统重建⼩⿏模型，例如⼈造⾎⼲细胞（HSC）移植；

验证信息：

5-FU对BRGSF小鼠结肠直肠癌移植的影响 

对BRGSF小鼠接入PDX，在肿瘤生长到100mm³的时候，注射5-FU（56 mg/kg）进行两次治疗；

• 5-FU具有抗肿瘤活性

更多详细数据请联系我们：联系我们 - 基锘威 - genOway (my3w.com)

案例

1. Homeostasis of monocytes and lung interstitial macrophages is regulated by collagen domain-binding receptor LAIR1 in vivo
2. Predictive in vivo evaluation of immunotherapy efficacy: tHIS is a reliable model
3. Deciphering high-dose IL-2 toxicity in reconstituted HIS mice 

评论

1. BRGSF-HIS: genOway’s mouse model to evaluate the pathogenesis of Staphylococcus aureus Panton-Valentine leukocidin in acute implant-associated osteomyelitis
2. Tumor grafts in preclinical research: Models, models, overall, who is the fittest of them all
3. Part 3: BRGSF-HIS, a new human immune system mouse model for immuno-oncology studies
4. Part 2: BRGSF, a new immunodeficient model for immuno-oncology studies

已发文献

1. VISTA checkpoint inhibition by pH-selective antibody SNS-101 with optimized safety and pharmacokinetic profiles enhances PD-1 response
2. Myeloid and dendritic cells enhance therapeutics-induced cytokine release syndrome features in humanized BRGSF-HIS preclinical model
3. Staphylococcus aureus Panton-Valentine Leukocidin worsens acute implant-associated osteomyelitis in humanized BRGSF mice
4. Imiquimod induces skin inflammation in humanized BRGSF mice with limited human immune cell activity
5. Frontline Science: Exhaustion and senescence marker profiles on human T cells in BRGSF-A2 humanized mice resemble those in human samples

海报

1. Tumor cell line-derived xenograft subtype shapes tumor microenvironment composition in BRGSF-HIS mice
2. Cell-depleting agents assessment in preclinical models
3. Myeloid cells' contribution is key in CRS pathophysiology induced by T-cell engagers in BRGSF-HIS model
4. Functional human myeloid cells in BRGSF-HIS humanized mice enable myeloid-directed therapy assessment
5. CD3 humanized mouse models as validated tools to assess immune-related adverse events of T-cell engagers
6. Anti-VISTA agents profiling: complementarity of BRGSF-HIS and hVISTA Knock-in as preclinical models for immunotherapies
7. Translatable preclinical mouse models for assessment of T-cell engager-induced CRS